Form 4: CervoMed CEO Boosts Stake with Open Market Share Purchases

CervoMed Inc.'s CEO and President, John J. Alam, acquired 21,600 shares of common stock through open-market transactions on November 17, 2025.

Summary

• John J. Alam, the CEO, President, Director, and 10% Owner of CervoMed Inc. (CRVO), reported open-market purchases of the company's common stock.
• On November 17, 2025, Mr. Alam acquired a total of 21,600 shares.
• This includes 10,807 shares purchased directly at a weighted average price of $8.46 per share, with prices ranging from $8.39 to $8.46.
• An additional 10,793 shares were acquired indirectly through his spouse's IRA at a weighted average price of $8.46 per share, with prices ranging from $8.38 to $8.50.
• Following these transactions, Mr. Alam beneficially owns 1,484,078 shares directly or jointly, which includes 1,471,578 shares held jointly with his spouse, Dr. Sylvie Gregoire (a Board Director), and 12,500 shares in his own Roth IRA.
• He also indirectly owns 12,500 shares through the Sylvie Gregoire Roth IRA.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to significant open-market purchases by the CEO and a 10% owner, indicating strong insider confidence in the company's valuation and future performance.

Positives

• The CEO and President, John J. Alam, increased his stake in CervoMed Inc. through open-market purchases, signaling strong confidence in the company's future prospects.
• The acquisition of 21,600 shares by a key insider demonstrates alignment of management's interests with those of shareholders.

Related Party Transactions

• Shares are held jointly by the Reporting Person and his spouse, Dr. Sylvie Gregoire, who is also a member of the Issuer's Board of Directors.
• Shares were acquired indirectly through the Sylvie Gregoire Roth IRA.

Stakeholder Impact

• Shareholders may view the increased insider ownership as a positive signal, potentially boosting investor confidence and demand for the stock.
• The transactions reinforce management's commitment and belief in the company's long-term value.

Key Dates

Recommendation

The significant open-market purchases by the CEO, who is also a 10% owner and director, at current market prices, strongly signals management's belief that the company's stock is undervalued or poised for future growth. Such insider buying is typically a strong positive indicator for investors, suggesting a 'buy' recommendation based on this filing.

Keywords

CervoMed, CRVO, insider buying, stock purchase, CEO, director, 10% owner, Form 4, beneficial ownership